Aim of this study is to evaluate in a population of osteoporotic chronic kidney disease patients the effect of denosumab:
* on coronary calcification scores evolution (by multidetector computed tomography) after 24 months of follow-up
* on abdominal aorta calcification scores evolution (by plain abdominal Xray) after 24 months of follow-up
* on bone mineral density (femoral T-score) (by bone densitometry) at 24 months
* on bone mineral density evolution (femoral T-score) (by bone densitometry) after 24 months of follow-up
* on bone mineral density evolution (lumbar T-score) (by bone densitometry) after 24 months of follow-up
* on parameters of bone remodelling after 24 months of follow-up
* on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of follow-up
* the tolerance after 24 months of follow-up
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic kidney disease stage 5D patient, hemodialyzed with extracorporeal treatment for at least 3 months
Osteoporosis
You may not be if
Pregnancy or breastfeeeding female
Current corticoid treatment
PTH and Calcium outside the KDIGO guidelines
Adynamic bone disease suspicion
Cancer or myeloma
Serious hepatic cytolysis
Serious dental troubles
Positive HIV serology
Hypersensibility to active substance or one of excipients of denosumab